InMed Pharmaceuticals Management
Management criteria checks 2/4
InMed Pharmaceuticals' CEO is Eric Adams, appointed in Jun 2016, has a tenure of 8.5 years. total yearly compensation is $415.40K, comprised of 70.8% salary and 29.2% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $10.24K. The average tenure of the management team and the board of directors is 4 years and 2.6 years respectively.
Key information
Eric Adams
Chief executive officer
US$415.4k
Total compensation
| CEO salary percentage | 70.8% |
| CEO tenure | 8.5yrs |
| CEO ownership | 0.3% |
| Management average tenure | 4yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$7m |
| Jun 30 2024 | US$415k | US$294k | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | n/a | n/a | -US$6m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | US$368k | US$278k | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | n/a | n/a | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | US$468k | US$363k | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | n/a | n/a | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | US$735k | US$328k | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | n/a | n/a | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | US$424k | US$287k | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$11m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | US$1m | US$287k | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$9m |
| Dec 31 2018 | n/a | n/a | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | US$2m | US$240k | -US$6m |
Compensation vs Market: Eric's total compensation ($USD415.40K) is below average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
CEO
Eric Adams (61 yo)
8.5yrs
Tenure
US$415,400
Compensation
Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.5yrs | US$415.40k | 0.31% $ 10.2k | |
| CFO & Corporate Secretary | less than a year | US$274.85k | 0% $ 0 | |
| Chief Operating Officer | 2.4yrs | US$349.20k | 0.00014% $ 4.7 | |
| Senior Vice President of Clinical & Regulatory Affairs | 8.2yrs | US$313.60k | 0% $ 0 | |
| Senior Vice President of Preclinical Research & Development | 6.8yrs | US$322.50k | 0.00042% $ 14.1 | |
| Co-Founder | no data | US$142.43k | no data | |
| VP of Accounting & Controller | 4.9yrs | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Vice President of Sales & Marketing | 2.8yrs | no data | no data | |
| Senior VP & GM of BayMedica | 3.2yrs | no data | no data | |
| Senior Consultant of Medical Affairs | no data | no data | no data |
4.0yrs
Average Tenure
58yo
Average Age
Experienced Management: INM's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.5yrs | US$415.40k | 0.31% $ 10.2k | |
| Independent Chair of the Board | 8.3yrs | US$77.50k | 0.27% $ 8.9k | |
| Independent Director | 2.6yrs | US$52.50k | 0% $ 0 | |
| Member of the Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.8yrs | US$52.50k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$52.50k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
2.6yrs
Average Tenure
59yo
Average Age
Experienced Board: INM's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 05:52 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InMed Pharmaceuticals Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |